111 related articles for article (PubMed ID: 38670563)
21. Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis.
Hong X; Qiu S; Ding B; Xu H; Shen Y
Ther Adv Med Oncol; 2024; 16():17588359231221336. PubMed ID: 38188470
[TBL] [Abstract][Full Text] [Related]
22. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
Morgan RD; Clamp AR; Hasan J; Mitchell C; Saunders G; Mescallado N; Welch R; Jayson GC
Int J Gynecol Cancer; 2018 Mar; 28(3):448-452. PubMed ID: 29466253
[TBL] [Abstract][Full Text] [Related]
23. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
24. Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.
Zou H; Xia L; Jin G; Wu H; Qian W; Jia D; Xu H; Li T
Cancer Manag Res; 2022; 14():1703-1711. PubMed ID: 35585940
[TBL] [Abstract][Full Text] [Related]
25. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients.
Huang A; Wang W; Qin R; Chen G; Gu A; Han B
J Cancer Res Ther; 2022 Sep; 18(5):1299-1305. PubMed ID: 36204876
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.
Jiang F; Li J; Kong X; Sun P; Qu H
Front Pharmacol; 2022; 13():973448. PubMed ID: 36238567
[No Abstract] [Full Text] [Related]
28. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
[TBL] [Abstract][Full Text] [Related]
30. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
31. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.
Lu S; Hong Y; Chen H; Wu L; Sun F; Wang J; Zhu J; Que Y; Zhang L; Zhen Z; Sun X; Huang J; Zhang Y
Front Pharmacol; 2022; 13():711704. PubMed ID: 35431969
[No Abstract] [Full Text] [Related]
32. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
33. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
34. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
She L; Su L; Shen L; Liu C
Front Oncol; 2021; 11():687564. PubMed ID: 34354945
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas.
Liu Z; Yao W; Zhao Y; Liu O; Zhang P; Ge H
Cancer Manag Res; 2021; 13():1009-1016. PubMed ID: 33574700
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial.
Li J; Tian Y; Zheng M; Ge J; Zhang J; Kong D; Chen M; Yu P
Thorac Cancer; 2022 Dec; 13(24):3496-3503. PubMed ID: 36346139
[TBL] [Abstract][Full Text] [Related]
37. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
van der Burg ME; de Wit R; van Putten WL; Logmans A; Kruit WH; Stoter G; Verweij J
Br J Cancer; 2002 Jan; 86(1):19-25. PubMed ID: 11857006
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis.
Yang Q; Guo C; Lin X; Luo L; He Z; Lin F; Zhang J; Chen Y; Jiang X; Ke C; Mou Y
Front Pharmacol; 2021; 12():804942. PubMed ID: 35002738
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
40. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]